NCT00416845已完成1 期
A Randomized, Parallel Group, Double-blind, Placebo Controlled, 14 Days Multiple-dose Treatment to Assess the Pulmonary and Cardiac Pharmacodynamics of FTY720 (0.5 and 1.25 mg) in Healthy Volunteers
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- Novartis
- 入组人数
- 39
- 试验地点
- 2
- 主要终点
- Effects of two doses of FTY720 on lung and cardiac (heart) functions in healthy volunteers.
研究概览
简要总结
This study is designed to assess the effects of two doses of FTY720 on lung (pulmonary) and cardiac (heart) functions in healthy volunteers.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 19 Years 至 50 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy, non-smoking,(ie. 6 months w/o the use of nicotine or nicotine containing products), male or female subjects.
- •Female subjects must be either surgically sterilized (including bilateral tubal ligation) at least 6 months or post-menopausal. Postmenopausal women must have no regular menstrual bleeding for at least 1 year prior to inclusion and menopause will be confirmed by a plasma FSH level of >40 IU/L.
- •Male subjects agree to refrain from sperm donation from check-in until 30 days beyond the conclusion of all study events.
- •Male subjects must agree to the use of condoms with spermicide with sexual intercourse from 14 days prior to check-in until 30 days beyond the last dose of study drug.
- •Resting heart rate ≥ 50 beats per minute (bpm)
排除标准
- •History or presence of any clinically significant events, which in the opinion of the investigator, would jeopardize the safety of the subject or impact the validity of the study results.
- •Subjects with systolic blood pressure < 90 mmHg or diastolic blood pressure < 50 mmHg
- •Male subjects with a QTcB > 450 msec
- •Female subjects with a QTcB > 470 msec
- •Subjects with pulmonary symptoms, history of exercise-induced asthma, asthma or chronic obstructive pulmonary disease (COPD)
- •Use of any prescription drug within 1 month of starting the study
- •Positive urine screen for alcohol or drugs at screening, unless the test is shown to be falsely positive on confirmation testing.
- •Hemoglobin < 12g/dL
- •Donation of blood or significant blood loss within 56 days prior to check in.
- •Donation of plasma within 7 days prior check in.
- •Participation in an investigational study within 30 days prior to check in.
- •Positive screening test for HIV or Hepatitis B or C.
- •A past history of cigarette smoking of > 10 pack-years or use of nicotine or nicotine-containing products 6 months prior to dosing.
- •Other protocol-defined inclusion/exclusion criteria may apply
结局指标
主要结局
Effects of two doses of FTY720 on lung and cardiac (heart) functions in healthy volunteers.
次要结局
- Treatment initiation effect on heart rhythm.
- Duration of dynamic effect on heart rate and rhythm.
- Treatment initiation effect and duration of this effect on cardiac output and stroke volume.
- Treatment initiation effect and the duration of this effect on pulmonary function with methacholine challenge.
- Pharmacodynamic effect on absolute lymphocyte count.
研究者
研究点 (2)
Loading locations...
相似试验
已完成
2 期
A Study of the Effect of FTY720 on Pulmonary Function in Patients With Moderate AsthmaAsthmaNCT00785083Novartis36
已完成
1 期
Pharmacokinetics (PK) and Metabolism of FTY720 in Patients With Severe Renal Impairment and Healthy Matched Subjects.Renal InsufficiencyNCT00731523Novartis18
已完成
2 期
Efficacy and Safety of FTY720 in Patients With Relapsing Multiple Sclerosis (MS)Multiple SclerosisNCT00537082Novartis171
已完成
不适用
COPD Aerosol Study Comparing the Efficacy of Nebulizers Versus Dry Powder InhalersCOPD ExacerbationNCT02291016University of Tennessee Graduate School of Medicine7
已完成
3 期
Characterization of Lung Function Profile of Inhaled Tiotropium + Olodaterol Fixed Dose Combination Compared to Fluticasone Propionate + Salmeterol Fixed Dose Combination in COPD PatientsPulmonary Disease, Chronic ObstructiveNCT01969721Boehringer Ingelheim229